Methods and materials for classification of tissue of origin of tumor samples

Abstract

The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.

1 .- 95 . (canceled) 
     
     
         96 . A method of identifying a tissue of origin of a cancer sample, said method comprising:
 (a) obtaining a biological sample from a subject in need thereof, wherein the sample is of a cancer selected from the group consisting of cancer of unknown primary (CUP), primary cancer, and metastatic cancer;   (b) measuring the level of nucleic acids comprising SEQ ID NOS: 1, 2 or 156, 3-7, 9-12, 14-21, 23-27, 29-40, 42, 43, 44 or 191, 45-51, 53-56, 57 or 202, 58, 59, 60 or 208, 61, 62 or 211, 64-69, 146-148, and optionally at least one control nucleic acid in the biological sample and applying a classifier algorithm to said level of nucleic acids measured; and   (c) identifying the tissue of origin of the sample based on the classification provided by the classifier algorithm.   
     
     
         97 . The method of  claim 96 , wherein the classifier algorithm is selected from the group consisting of: decision tree classifier, K-nearest neighbor classifier (KNN), logistic regression classifier, nearest neighbor classifier, neural network classifier, Gaussian mixture model (GMM), Support Vector Machine (SVM) classifier, nearest centroid classifier, linear regression classifier and random forest classifier. 
     
     
         98 . The method of  claim 96 , wherein the cancer is selected from the group consisting of adrenocortical carcinoma; anus or skin squamous cell carcinoma; biliary tract adenocarcinoma; Ewing sarcoma; gastrointestinal stromal tumor (GIST); gastrointestinal tract carcinoid; renal cell carcinoma: chromophobe, clear cell and papillary; pancreatic islet cell tumor; pheochromocytoma; urothelial cell carcinoma (TCC); lung, head & neck, or esophagus squamous cell carcinoma (SCC); brain: astrocytic tumor, oligodendroglioma; breast adenocarcinoma; uterine cervix squamous cell carcinoma; chondrosarcoma; germ cell cancer; sarcoma; colorectal adenocarcinoma; liposarcoma; hepatocellular carcinoma (HCC); lung large cell or adenocarcinoma; lung carcinoid; pleural mesothelioma; lung small cell carcinoma; B-cell lymphoma; T-cell lymphoma; melanoma; malignant fibrous histiocytoma (MFH) or fibrosarcoma; osteosarcoma; ovarian primitive germ cell tumor; ovarian carcinoma; pancreatic adenocarcinoma; prostate adenocarcinoma; rhabdomyosarcoma; gastric or esophageal adenocarcinoma; synovial sarcoma; non-seminomatous testicular germ cell tumor; seminomatous testicular germ cell tumor; thymoma; thymic carcinoma; follicular thyroid carcinoma; medullary thyroid carcinoma; and papillary thyroid carcinoma. 
     
     
         99 . The method of  claim 98 , wherein a level of SEQ ID NOS: 55 above the reference threshold indicates a cancer of germ cell origin selected from the group consisting of an ovarian primitive cell and a testis cell, and further wherein a level of SEQ ID NOS: 29 and 62 above the reference threshold indicates a testis cell cancer origin selected from the group consisting of seminomatous testicular germ cell and non-seminomatous testicular germ cell. 
     
     
         100 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 9 and 29 above the reference threshold indicates a cancer origin selected from the group consisting of biliary tract adenocarcinoma and hepatocellular carcinoma. 
     
     
         101 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 16, 156, 66 and 68 above the reference threshold indicates a cancer of brain origin, and further wherein a level of SEQ ID NOS: 40 and 60 above the reference threshold indicates a brain cancer origin selected from the group consisting of oligodendroglioma and astrocytoma. 
     
     
         102 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 27, 35, 14 and 21 above the reference threshold indicates a cancer of prostate adenocarcinoma origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 27, 35, 14, 21, 32, 51, 7, 25, 50, 11, 148, 4, 49 and 67 above the reference threshold indicates a cancer of breast adenocarcinoma origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 27, 35, 14, 21, 32, 51, 7, 25, 4, 39, 50, 11, 148, 49, 67, 57 and 34 above the reference threshold indicates a cancer of an ovarian carcinoma origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 27, 35, 14, 21, 32, 51, 7, 11, 148, 4, 49, 67, 57 and 34 above the reference threshold indicates a cancer of lung large cell or lung adenocarcinoma origin; and wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 20 and 45 above the reference threshold indicates a cancer of lung small cell carcinoma origin. 
     
     
         103 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 27, 35, 14, 21, 32, 51, 7, 11, 148 and 4 above the reference threshold indicates a cancer of thyroid carcinoma origin, and further wherein a level of SEQ ID NOS: 17 and 34 above the threshold indicates that the thyroid carcinoma origin is follicular or papillary. 
     
     
         104 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 27, 35, 14, 21, 32, 51, 7, 50, 4, 39, 3 and 34 above the reference threshold indicates a cancer of a thymic carcinoma origin; or wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 27, 35, 14, 21, 32, 51, 7, 50, 4, 39, 3, 34, 69, 24 and 44 above the reference threshold indicates a cancer of urothelial cell carcinoma or squamous cell carcinoma origin, and further wherein a level of SEQ ID NOS: 1, 5 and 54 above the reference threshold indicates that the squamous-cell-carcinoma origin is uterine cervix squamous-cell—carcinoma or non-uterine cervix squamous cell carcinoma; or further wherein a level of SEQ ID NOS: 11 and 23 above the reference threshold indicates that the non-uterine cervix squamous cell carcinoma origin is selected from the group consisting of: a) anus or skin squamous cell carcinoma, and b) lung, head & neck, and esophagus squamous cell carcinoma. 
     
     
         105 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 16, 2, 47 and 50 above the reference threshold indicates a cancer of melanoma or lymphoma origin, and further wherein a level of SEQ ID NOS: 35 and 48 above the reference threshold indicates that the lymphoma cancer origin is selected from the group consisting of B-cell lymphoma and T-cell lymphoma. 
     
     
         106 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 20, 45, 40, 67 and 68 above the reference threshold indicates a cancer of medullary thyroid carcinoma origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 20, 45, 40, 67, 68, 64, 53 and 37 above the reference threshold indicates a cancer of lung carcinoid origin; and wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 20, 45, 40, 67, 68, 64, 53, 37, 34 and 18 above the reference threshold indicates a cancer of gastrointestinal tract carcinoid or pancreatic islet cell tumor origin. 
     
     
         107 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 27, 35, 42, 36 and 146 above the reference threshold indicates a cancer of gastric or esophageal adenocarcinoma origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 27, 35, 42, 36, 146, 20 and 43 above the reference threshold indicates a cancer of colorectal adenocarcinoma origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 56, 65, 25, 27, 35, 42, 36, 146, 20, 43, 51, 49 and 16 above the reference threshold indicates a cancer of pancreatic adenocarcinoma or biliary tract adenocarcinoma origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 16, 2, 66, 68, 19 and 29 above the reference threshold indicates a cancer of renal cell carcinoma origin, and further wherein a level of SEQ ID NOS: 36 and 147 above the reference threshold indicates a chromophobe renal cell carcinoma origin, or further wherein a level of SEQ ID NOS: 49 and 9 above the reference threshold indicates that the renal cell carcinoma origin is clear cell or papillary. 
     
     
         108 . The method of  claim 98 , wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 16, 2, 66, 68, 19, 29, 65 and 56 above the reference threshold indicates a cancer of pheochromocytoma origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 16, 2, 66, 68, 19, 29, 65, 56, 31, 38 and 61 above the reference threshold indicates a cancer of adrenocortical origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 16, 2, 66, 68, 19, 29, 65, 56, 31, 38, 61, 14 and 45 above the reference threshold indicates a cancer of gastrointestinal stromal tumor origin; wherein a level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 55, 6, 30, 46, 16, 2, 66, 68, 19, 29, 65, 56, 31, 38, 61, 14, 45, 35, 10 and 5 above the reference threshold indicates a cancer of pleural mesothelioma or sarcoma origin, and further wherein a level of SEQ ID NOS: 3, 40 and 15 above the reference threshold indicates that the sarcoma is synovial sarcoma, or further wherein a level of SEQ ID NOS: 3, 40, 15, 12 and 58 above the reference threshold indicates that the sarcoma is chondrosarcoma, or further wherein a level of SEQ ID NOS: 3, 40, 15, 12, 58, 36 and 26 above the reference threshold indicates that the sarcoma is liposarcoma, or further wherein a level of SEQ ID NOS: 3, 40, 15, 12, 58, 36, 26, 21, 25 and 49 above the reference threshold indicates that the sarcoma is Ewing sarcoma or osteosarcoma; or further wherein a level of SEQ ID NOS: 3, 40, 15, 12, 58, 36, 26, 21, 59, 39 and 33 above the reference threshold indicates that the sarcoma is selected from the group consisting of: a) rhabdomyosarcoma, and b) malignant fibrous histiocytoma and fibrosarcoma. 
     
     
         109 . The method of  claim 96 , wherein the biological sample is selected from the group consisting of a bodily fluid, a cell line, a tissue sample, a biopsy sample, a needle biopsy sample, a fine needle biopsy (FNA) sample, a surgically removed sample, and a sample obtained by tissue-sampling procedures such as endoscopy, bronchoscopy, or laparoscopic methods. 
     
     
         110 . The method of  claim 109 , wherein the tissue is a fresh, frozen, fixed, wax-embedded or formalin-fixed paraffin-embedded (FFPE) tissue. 
     
     
         111 . The method of  claim 96 , wherein the level of the nucleic acid sequence is determined by a method selected from the group consisting of nucleic acid hybridization and nucleic acid amplification. 
     
     
         112 . The method of  claim 113 , wherein nucleic acid hybridization is performed using a solid-phase nucleic acid biochip array or in situ hybridization and wherein nucleic acid amplification is real-time PCR comprising forward and reverse primers and a probe comprising a sequence selected from the group consisting of a sequence that is complementary to a sequence selected from SEQ ID NOS: 1, 2 or 156, 3-7, 9-12, 14-21, 23-27, 29-40, 42, 43, 44 or 191, 45-51, 53-56, 57 or 202, 58, 59, 60 or 208, 61, 62 or 211, 64-69, 146-148, and optionally at least one control nucleic acid and a fragment thereof. 
     
     
         113 . A kit for performing the method of  claim 96  comprising probes, wherein the probes comprise (i) DNA equivalents of nucleic acids comprising SEQ ID NOS: 1-7, 9-12, 14-21, 23-27, 29-40, 42-51, 53-57, 59-62, 64-69, 146-148, and 156, (ii) the complements thereof, or (iii) sequences at least 90% identical to (i) or (ii).